An enhancer within tumors provides a potential target for 'undruggable' MYC in pediatric medulloblastoma

Efforts to develop effective therapies for MYC-amplified Group 3 medulloblastoma (G3-MB) are hindered by an incomplete understanding of how MYC expression is controlled in these tumors. MYC, an oncogene, has long been considered "undruggable," because it lacks clear pockets for drugs to bind and inh